Connection

Jordan Elm to Female

Back to Details
This is a "connection" page, showing publications Jordan Elm has written about Female.
Jordan Elm
Connection Strength
0.413
Female
  1. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21.
    View in: PubMed
    Score: 0.023
  2. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.016
  3. Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled Trial. Stroke. 2023 Apr; 54(4):912-920.
    View in: PubMed
    Score: 0.012
  4. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. 2021 08 17; 97(7):e720-e727.
    View in: PubMed
    Score: 0.010
  5. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure. Clin Transl Sci. 2021 07; 14(4):1444-1451.
    View in: PubMed
    Score: 0.010
  6. Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus. Neurology. 2021 05 11; 96(19):e2372-e2386.
    View in: PubMed
    Score: 0.010
  7. Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial. J Am Heart Assoc. 2021 03 16; 10(6):e019362.
    View in: PubMed
    Score: 0.010
  8. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. J Clin Pharmacol. 2021 06; 61(6):763-768.
    View in: PubMed
    Score: 0.010
  9. BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
    View in: PubMed
    Score: 0.010
  10. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020 07; 51(7):2058-2065.
    View in: PubMed
    Score: 0.010
  11. The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia. 2020 06; 61(6):e66-e70.
    View in: PubMed
    Score: 0.010
  12. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020 04 11; 395(10231):1217-1224.
    View in: PubMed
    Score: 0.009
  13. Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial. Stroke. 2020 03; 51(3):792-799.
    View in: PubMed
    Score: 0.009
  14. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. N Engl J Med. 2019 11 28; 381(22):2103-2113.
    View in: PubMed
    Score: 0.009
  15. Lessons from the Established Status Epilepticus Treatment Trial. Epilepsy Behav. 2019 12; 101(Pt B):106296.
    View in: PubMed
    Score: 0.009
  16. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
    View in: PubMed
    Score: 0.009
  17. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019 07 01; 76(7):774-782.
    View in: PubMed
    Score: 0.009
  18. Factors Influencing Oral Intake Improvement and Feeding Tube Dependency in Patients with Poststroke Dysphagia. J Stroke Cerebrovasc Dis. 2019 Jun; 28(6):1421-1430.
    View in: PubMed
    Score: 0.009
  19. Mapping acute lesion locations to physiological swallow impairments after stroke. Neuroimage Clin. 2019; 22:101685.
    View in: PubMed
    Score: 0.009
  20. Statistical Methodology for Multiclass Classifications: Applications to Dementia. J Alzheimers Dis. 2019; 68(1):173-186.
    View in: PubMed
    Score: 0.009
  21. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease. BMC Med Inform Decis Mak. 2018 12 20; 18(1):138.
    View in: PubMed
    Score: 0.009
  22. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018 12 01; 75(12):1470-1476.
    View in: PubMed
    Score: 0.009
  23. Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial. Neurology. 2018 12 04; 91(23):e2163-e2169.
    View in: PubMed
    Score: 0.009
  24. Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage. Stroke. 2018 11; 49(11):2652-2658.
    View in: PubMed
    Score: 0.009
  25. BDNF genotype and tDCS interaction in aphasia treatment. Brain Stimul. 2018 Nov - Dec; 11(6):1276-1281.
    View in: PubMed
    Score: 0.008
  26. Long-Term Outcomes in Patients Aged =70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis. Stroke. 2018 06; 49(6):1457-1463.
    View in: PubMed
    Score: 0.008
  27. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19; 379(3):215-225.
    View in: PubMed
    Score: 0.008
  28. Differences in swallow physiology in patients with left and right hemispheric strokes. Physiol Behav. 2018 10 01; 194:144-152.
    View in: PubMed
    Score: 0.008
  29. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017 Nov; 82(5):755-765.
    View in: PubMed
    Score: 0.008
  30. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143.
    View in: PubMed
    Score: 0.008
  31. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
    View in: PubMed
    Score: 0.008
  32. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 12; 33:127-133.
    View in: PubMed
    Score: 0.007
  33. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct; 15(11):1160-9.
    View in: PubMed
    Score: 0.007
  34. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.
    View in: PubMed
    Score: 0.007
  35. Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design. Neurocrit Care. 2016 Feb; 24(1):132-9.
    View in: PubMed
    Score: 0.007
  36. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002.
    View in: PubMed
    Score: 0.007
  37. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
    View in: PubMed
    Score: 0.007
  38. Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale. J Parkinsons Dis. 2015; 5(1):67-73.
    View in: PubMed
    Score: 0.007
  39. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis. 2015; 5(4):731-6.
    View in: PubMed
    Score: 0.007
  40. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
    View in: PubMed
    Score: 0.007
  41. Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care. 2014 Apr; 20(2):193-201.
    View in: PubMed
    Score: 0.006
  42. Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord. 2014 Feb; 29(2):263-5.
    View in: PubMed
    Score: 0.006
  43. Pilot study of intravenous glyburide in patients with a large ischemic stroke. Stroke. 2014 Jan; 45(1):281-3.
    View in: PubMed
    Score: 0.006
  44. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke. 2013 Aug; 8(6):479-83.
    View in: PubMed
    Score: 0.006
  45. Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013 Aug; 22(6):742-9.
    View in: PubMed
    Score: 0.005
  46. How common is brain atrophy in patients with medial temporal lobe epilepsy? Epilepsia. 2010 Sep; 51(9):1774-9.
    View in: PubMed
    Score: 0.005
  47. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12.
    View in: PubMed
    Score: 0.005
  48. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.005
  49. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.